Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pigmented Villonodular Synovitis - Overview
Pigmented Villonodular Synovitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pigmented Villonodular Synovitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Checkmate Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Nippon Chemiphar Co Ltd
Novartis AG
Pigmented Villonodular Synovitis - Drug Profiles
avelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabiralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emactuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zaltoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pigmented Villonodular Synovitis - Dormant Projects
Pigmented Villonodular Synovitis - Discontinued Products
Pigmented Villonodular Synovitis - Product Development Milestones
Featured News & Press Releases
Jun 01, 2014: Roche to present phase I data on investigatiol cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Pigmented Villonodular Synovitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Pigmented Villonodular Synovitis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pigmented Villonodular Synovitis - Pipeline by Bristol-Myers Squibb Co, H2 2020
Pigmented Villonodular Synovitis - Pipeline by Checkmate Pharmaceuticals Inc, H2 2020
Pigmented Villonodular Synovitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Pigmented Villonodular Synovitis - Pipeline by Merck KGaA, H2 2020
Pigmented Villonodular Synovitis - Pipeline by Nippon Chemiphar Co Ltd, H2 2020
Pigmented Villonodular Synovitis - Pipeline by Novartis AG, H2 2020
Pigmented Villonodular Synovitis - Dormant Projects, H2 2020
Pigmented Villonodular Synovitis - Discontinued Products, H2 2020